Dr Doris Hansen speaks to ecancer about a study presented at ASH 2024 into idecabtagene vicleucel, the first FDA-approved BCMA-directed CAR T-cell therapy for patients with prior treatments.

She reports that this retrospective study containing 108 patients saw that pre-treatment burden posed a high risk of immune effector cell-associated neurotoxicity syndrome, whereas higher cell doses associated with higher grade cytokine release syndrome.